Cognitive Impairment Associated With Schizophrenia (CIAS)Pipeline Review, H2 2015
Summary
Global Markets Directs, Cognitive Impairment Associated With Schizophrenia (CIAS)Pipeline Review, H2 2015, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10
Therapeutics Development 11
Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 11
Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis 12
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 13
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 18
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 20
AbbVie Inc. 20
Amarantus Bioscience Holdings, Inc. 21
Astellas Pharma Inc. 22
Avineuro Pharmaceuticals, Inc. 23
Bristol-Myers Squibb Company 24
Eli Lilly and Company 25
FORUM Pharmaceuticals Inc. 26
H. Lundbeck A/S 27
Intra-Cellular Therapies, Inc. 28
Iproteos S.L. 29
Mnemosyne Pharmaceuticals, Inc. 30
Neuralstem, Inc. 31
Pfizer Inc. 32
Saniona AB 33
Siena Biotech S.p.A. 34
SK Biopharmaceuticals Co., Ltd. 35
Sunovion Pharmaceuticals Inc. 36
Takeda Pharmaceutical Company Limited 37
Upsher-Smith Laboratories, Inc. 38
Vanda Pharmaceuticals Inc. 39
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
A-431404 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AN-761 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AQW-051 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ASP-4345 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ASP-5736 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AUT-1 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AUT-6 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AUT-9 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AVL-3288 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AVN-211 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DSP-3748 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
eltoprazine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
encenicline hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
erteberel - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IC-041 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IPR-001 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
IPR-088 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
IPR-19 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ITI-214 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
LUAF-64280 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
NSI-189 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PF-04958242 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PNU-120596 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
roflumilast - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SEN-15924 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
SKL-15508 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SKL-A4R - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Agonize NMDA2B for CIAS - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TAK-058 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TAK-915 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Cognitive Impairment Associated With Schizophrenia (CIAS) - Recent Pipeline Updates 89
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects 101
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products 103
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones 104
Featured News & Press Releases 104
Sep 14, 2015: FORUM Pharmaceuticals Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer’s Disease and Cognitive Impairment in Schizophrenia 104
Jul 15, 2015: FORUM Pharmaceuticals Announces Publication of Encenicline Phase 2 Clinical Trial Results for Cognitive Impairment in Schizophrenia 104
Jun 22, 2015: FORUM Pharmaceuticals Receives FDA Fast Track Designation for Lead Compound Encenicline to Treat Cognitive Impairment in Schizophrenia 105
Jun 11, 2015: FORUM Pharmaceuticals Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia 106
Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 107
Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110
List of Tables
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2015 11
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H2 2015 20
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015 21
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc., H2 2015 22
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2015 23
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H2 2015 24
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2015 25
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H2 2015 26
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2015 27
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 28
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H2 2015 29
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015 30
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem, Inc., H2 2015 31
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H2 2015 32
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2015 33
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Siena Biotech S.p.A., H2 2015 34
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 35
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 36
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 37
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015 38
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc., H2 2015 39
Assessment by Monotherapy Products, H2 2015 40
Number of Products by Stage and Target, H2 2015 42
Number of Products by Stage and Mechanism of Action, H2 2015 44
Number of Products by Stage and Route of Administration, H2 2015 46
Number of Products by Stage and Molecule Type, H2 2015 48
Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Recent Pipeline Updates, H2 2015 89
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2015 101
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H2 2015 102
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2015 103
List of Figures
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2015 11
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 40
Number of Products by Top 10 Targets, H2 2015 41
Number of Products by Stage and Top 10 Targets, H2 2015 41
Number of Products by Top 10 Mechanism of Actions, H2 2015 43
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 43
Number of Products by Top 10 Routes of Administration, H2 2015 45
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 45
Number of Products by Top 10 Molecule Types, H2 2015 47
Number of Products by Stage and Top 10 Molecule Types, H2 2015 47
